Understanding Barriers to Enrollment in Adjuvant Clinical Trials: Insights into Patient Eligibility Criteria from the Adjuvant S-1 for Cholangiocarcinoma Trial (JCOG1202, ASCOT)

Affiliations

¹ Division of Surgical Oncology, Department of Surgery, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
² Division of Surgical Oncology, Department of Surgery, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. mayos@ohsu.edu.

Editorial

Divya Sood et al. Ann Surg Oncol. 2023 Nov.

. 2023 Nov;30(12):6967-6969.

doi: 10.1245/s10434-023-14272-y. Epub 2023 Sep 8.

¹ Division of Surgical Oncology, Department of Surgery, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
² Division of Surgical Oncology, Department of Surgery, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. mayos@ohsu.edu.

No abstract available

Comment on

A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).
Kobayashi S, Ikeda M, Nakachi K, Ueno M, Okusaka T, Todaka A, Satoi S, Tomokuni A, Konishi M, Furuse J. Kobayashi S, et al. Ann Surg Oncol. 2023 Nov;30(12):7331-7337. doi: 10.1245/s10434-023-13913-6. Epub 2023 Jul 14. Ann Surg Oncol. 2023. PMID: 37450093

1. Bouzalmate-Hajjaj A, Massó Guijarro P, Khan KS, Bueno-Cavanillas A, Cano-Ibáñez N. Benefits of participation in clinical trials: an umbrella review. Int J Environ Res Public Health. 2022;19(22):15368. - DOI - PubMed - PMC
1. Kobayashi S, Ikeda M, Nakachi K, et al. A multicenter survey on eligibility for a randomized, phase III trial of adjuvant chemotherapy for resected biliary tract cancer (JCOG1202, ASCOT). Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13913-6 . - DOI - PubMed - PMC
1. Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomized, controlled, phase 3 trial. Lancet. 2023;401(10372):195–203. - DOI - PubMed
1. Unger JM, Fleury M. Nationally representative estimates of the participation of cancer patients in clinical research studies according to the commission on cancer. J Clin Oncol. 2021;39(28):74–74. - DOI
1. Chino F, Zafar SY. Financial toxicity and equitable access to clinical trials. Am Soc Clin Oncol Educ Book. 2019;39:11–8. - DOI - PubMed